Literature DB >> 1120929

Defective regulation of chemotaxis in cirrhosis.

E C Maderazo, P A Ward, R Quintiliani.   

Abstract

The presence of a severe leukotactic defect in cirrhotic patients has been confirmed. This defect is due to the presence of abnormally high levels of the chemotactic factor inactivator (CFI) in serums of patients with hepatic cirrhosis. This inactivator inhibits each of three different chemotactic factors tested and does so in an irreversible manner. As would be predicted by these results, generation of chemotactic activity in cirrhotic serums by a complement-activating agent is markedly impaired. Physicochemical features of CFI in cirrhotic serum differ slightly from that found in normal human serum. These results indicate the nature of the chemotactic defect in cirrhotic patients and may explain the increased susceptibility of these patients to bacterial infections and some of their reported defected in expression of cellular immunity.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1120929

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  20 in total

Review 1.  Problems of bacterial infection in patients with liver disease.

Authors:  R J Wyke
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

Review 2.  Pathologic aspects of cirrhosis. A review.

Authors:  H Popper
Journal:  Am J Pathol       Date:  1977-04       Impact factor: 4.307

Review 3.  Macrophage activation, chronic inflammation and gastrointestinal disease.

Authors:  A R Tanner; M J Arthur; R Wright
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

4.  Defects in serum attractant activity in different types of chronic liver disease.

Authors:  A G Yousif-Kadaru; I A Rajkovic; R J Wyke; R Williams
Journal:  Gut       Date:  1984-01       Impact factor: 23.059

5.  Serum IgA: modulation of complement activation and induction of susceptibility to bacterial dissemination.

Authors:  J M Griffiss
Journal:  Infection       Date:  1982       Impact factor: 3.553

6.  In vivo assessment of granulocyte migration to diseased bowel in Crohn's disease.

Authors:  S H Saverymuttu; A M Peters; J P Lavender; V S Chadwick; H J Hodgson
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

7.  Transient improvement of polymorphonuclear leukocyte function by splenectomy in beta-thalassemia.

Authors:  P E Lianou; H P Bassaris; A T Skoutelis; E G Votta; J T Papavassiliou; J P Phair
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

8.  A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.

Authors:  H D Perez; M Lipton; I M Goldstein
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

9.  Neutrophil adherence in chronic liver disease and fulminant hepatic failure.

Authors:  M Altin; I A Rajkovic; R D Hughes; R Williams
Journal:  Gut       Date:  1983-08       Impact factor: 23.059

10.  Measurement of granulocyte migration and accumulation in inflammation in man.

Authors:  S H Saverymuttu; A M Peters; H J Reavy; J P Lavender
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.